世界の代謝型グルタミン酸受容体3市場 2021：企業別、地域別、種類・用途別

• 英文タイトル：Global Metabotropic Glutamate Receptor 3 Market 2021 by Company, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-107A15029 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、84ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥522,000 (USD3,480)	▷ お問い合わせ
Multi User	￥783,000 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,044,000 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料では、代謝型グルタミン酸受容体3のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。代謝型グルタミン酸受容体3の種類別市場規模（LY-3020371、VU-0092273、DT-010991、その他）、用途別市場規模（自閉症、慢性疼痛、神経膠腫、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・代謝型グルタミン酸受容体3の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Addex Therapeutics Ltd、Aevi Genomic Medicine Inc、Denovo Biopharma LLC、Domain Therapeutics SA、Eli Lilly and Company、Prexton Therapeutics SA ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：LY-3020371、VU-0092273、DT-010991、その他 ・用途別分析2016年-2026年：自閉症、慢性疼痛、神経膠腫、その他 ・代謝型グルタミン酸受容体3の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・代謝型グルタミン酸受容体3のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・代謝型グルタミン酸受容体3のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・代謝型グルタミン酸受容体3の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・代謝型グルタミン酸受容体3の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Metabotropic Glutamate Receptor 3 market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Metabotropic Glutamate Receptor 3 size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Metabotropic Glutamate Receptor 3 market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Metabotropic Glutamate Receptor 3 market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
LY-3020371
VU-0092273
DT-010991
Others

Market segment by Application, can be divided into
Autism
Chronic Pain
Glioma
Others

Market segment by players, this report covers
Addex Therapeutics Ltd
Aevi Genomic Medicine Inc
Denovo Biopharma LLC
Domain Therapeutics SA
Eli Lilly and Company
Prexton Therapeutics SA

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Metabotropic Glutamate Receptor 3 product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Metabotropic Glutamate Receptor 3, with revenue, gross margin and global market share of Metabotropic Glutamate Receptor 3 from 2019 to 2021.
Chapter 3, the Metabotropic Glutamate Receptor 3 competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Metabotropic Glutamate Receptor 3 market forecast, by regions, type and application, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe Metabotropic Glutamate Receptor 3 research findings and conclusion, appendix and data source.

レポート目次

---

1 Market Overview
1.1 Product Overview and Scope of Metabotropic Glutamate Receptor 3
1.2 Classification of Metabotropic Glutamate Receptor 3 by Type
1.2.1 Overview: Global Metabotropic Glutamate Receptor 3 Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Metabotropic Glutamate Receptor 3 Revenue Market Share by Type in 2020
1.2.3 LY-3020371
1.2.4 VU-0092273
1.2.5 DT-010991
1.2.6 Others
1.3 Global Metabotropic Glutamate Receptor 3 Market by Application
1.3.1 Overview: Global Metabotropic Glutamate Receptor 3 Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Autism
1.3.3 Chronic Pain
1.3.4 Glioma
1.3.5 Others
1.4 Global Metabotropic Glutamate Receptor 3 Market Size & Forecast
1.5 Global Metabotropic Glutamate Receptor 3 Market Size and Forecast by Region
1.5.1 Global Metabotropic Glutamate Receptor 3 Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Metabotropic Glutamate Receptor 3 Market Size by Region, (2016-2021)
1.5.3 North America Metabotropic Glutamate Receptor 3 Market Size and Prospect (2016-2026)
1.5.4 Europe Metabotropic Glutamate Receptor 3 Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Metabotropic Glutamate Receptor 3 Market Size and Prospect (2016-2026)
1.5.6 South America Metabotropic Glutamate Receptor 3 Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Metabotropic Glutamate Receptor 3 Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Metabotropic Glutamate Receptor 3 Market Drivers
1.6.2 Metabotropic Glutamate Receptor 3 Market Restraints
1.6.3 Metabotropic Glutamate Receptor 3 Trends Analysis
2 Company Profiles
2.1 Addex Therapeutics Ltd
2.1.1 Addex Therapeutics Ltd Details
2.1.2 Addex Therapeutics Ltd Major Business
2.1.3 Addex Therapeutics Ltd Metabotropic Glutamate Receptor 3 Product and Solutions
2.1.4 Addex Therapeutics Ltd Metabotropic Glutamate Receptor 3 Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Addex Therapeutics Ltd Recent Developments and Future Plans
2.2 Aevi Genomic Medicine Inc
2.2.1 Aevi Genomic Medicine Inc Details
2.2.2 Aevi Genomic Medicine Inc Major Business
2.2.3 Aevi Genomic Medicine Inc Metabotropic Glutamate Receptor 3 Product and Solutions
2.2.4 Aevi Genomic Medicine Inc Metabotropic Glutamate Receptor 3 Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Aevi Genomic Medicine Inc Recent Developments and Future Plans
2.3 Denovo Biopharma LLC
2.3.1 Denovo Biopharma LLC Details
2.3.2 Denovo Biopharma LLC Major Business
2.3.3 Denovo Biopharma LLC Metabotropic Glutamate Receptor 3 Product and Solutions
2.3.4 Denovo Biopharma LLC Metabotropic Glutamate Receptor 3 Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Denovo Biopharma LLC Recent Developments and Future Plans
2.4 Domain Therapeutics SA
2.4.1 Domain Therapeutics SA Details
2.4.2 Domain Therapeutics SA Major Business
2.4.3 Domain Therapeutics SA Metabotropic Glutamate Receptor 3 Product and Solutions
2.4.4 Domain Therapeutics SA Metabotropic Glutamate Receptor 3 Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Domain Therapeutics SA Recent Developments and Future Plans
2.5 Eli Lilly and Company
2.5.1 Eli Lilly and Company Details
2.5.2 Eli Lilly and Company Major Business
2.5.3 Eli Lilly and Company Metabotropic Glutamate Receptor 3 Product and Solutions
2.5.4 Eli Lilly and Company Metabotropic Glutamate Receptor 3 Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Eli Lilly and Company Recent Developments and Future Plans
2.6 Prexton Therapeutics SA
2.6.1 Prexton Therapeutics SA Details
2.6.2 Prexton Therapeutics SA Major Business
2.6.3 Prexton Therapeutics SA Metabotropic Glutamate Receptor 3 Product and Solutions
2.6.4 Prexton Therapeutics SA Metabotropic Glutamate Receptor 3 Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Prexton Therapeutics SA Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Metabotropic Glutamate Receptor 3 Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Metabotropic Glutamate Receptor 3 Players Market Share
3.2.2 Top 10 Metabotropic Glutamate Receptor 3 Players Market Share
3.2.3 Market Competition Trend
3.3 Metabotropic Glutamate Receptor 3 Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Metabotropic Glutamate Receptor 3 Revenue and Market Share by Type (2016-2021)
4.2 Global Metabotropic Glutamate Receptor 3 Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Metabotropic Glutamate Receptor 3 Revenue Market Share by Application (2016-2021)
5.2 Metabotropic Glutamate Receptor 3 Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Metabotropic Glutamate Receptor 3 Revenue by Type (2016-2026)
6.2 North America Metabotropic Glutamate Receptor 3 Revenue by Application (2016-2026)
6.3 North America Metabotropic Glutamate Receptor 3 Market Size by Country
6.3.1 North America Metabotropic Glutamate Receptor 3 Revenue by Country (2016-2026)
6.3.2 United States Metabotropic Glutamate Receptor 3 Market Size and Forecast (2016-2026)
6.3.3 Canada Metabotropic Glutamate Receptor 3 Market Size and Forecast (2016-2026)
6.3.4 Mexico Metabotropic Glutamate Receptor 3 Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Metabotropic Glutamate Receptor 3 Revenue by Type (2016-2026)
7.2 Europe Metabotropic Glutamate Receptor 3 Revenue by Application (2016-2026)
7.3 Europe Metabotropic Glutamate Receptor 3 Market Size by Country
7.3.1 Europe Metabotropic Glutamate Receptor 3 Revenue by Country (2016-2026)
7.3.2 Germany Metabotropic Glutamate Receptor 3 Market Size and Forecast (2016-2026)
7.3.3 France Metabotropic Glutamate Receptor 3 Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Metabotropic Glutamate Receptor 3 Market Size and Forecast (2016-2026)
7.3.5 Russia Metabotropic Glutamate Receptor 3 Market Size and Forecast (2016-2026)
7.3.6 Italy Metabotropic Glutamate Receptor 3 Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Metabotropic Glutamate Receptor 3 Revenue by Type (2016-2026)
8.2 Asia-Pacific Metabotropic Glutamate Receptor 3 Revenue by Application (2016-2026)
8.3 Asia-Pacific Metabotropic Glutamate Receptor 3 Market Size by Region
8.3.1 Asia-Pacific Metabotropic Glutamate Receptor 3 Revenue by Region (2016-2026)
8.3.2 China Metabotropic Glutamate Receptor 3 Market Size and Forecast (2016-2026)
8.3.3 Japan Metabotropic Glutamate Receptor 3 Market Size and Forecast (2016-2026)
8.3.4 South Korea Metabotropic Glutamate Receptor 3 Market Size and Forecast (2016-2026)
8.3.5 India Metabotropic Glutamate Receptor 3 Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Metabotropic Glutamate Receptor 3 Market Size and Forecast (2016-2026)
8.3.7 Australia Metabotropic Glutamate Receptor 3 Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Metabotropic Glutamate Receptor 3 Revenue by Type (2016-2026)
9.2 South America Metabotropic Glutamate Receptor 3 Revenue by Application (2016-2026)
9.3 South America Metabotropic Glutamate Receptor 3 Market Size by Country
9.3.1 South America Metabotropic Glutamate Receptor 3 Revenue by Country (2016-2026)
9.3.2 Brazil Metabotropic Glutamate Receptor 3 Market Size and Forecast (2016-2026)
9.3.3 Argentina Metabotropic Glutamate Receptor 3 Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Metabotropic Glutamate Receptor 3 Revenue by Type (2016-2026)
10.2 Middle East & Africa Metabotropic Glutamate Receptor 3 Revenue by Application (2016-2026)
10.3 Middle East & Africa Metabotropic Glutamate Receptor 3 Market Size by Country
10.3.1 Middle East & Africa Metabotropic Glutamate Receptor 3 Revenue by Country (2016-2026)
10.3.2 Turkey Metabotropic Glutamate Receptor 3 Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Metabotropic Glutamate Receptor 3 Market Size and Forecast (2016-2026)
10.3.4 UAE Metabotropic Glutamate Receptor 3 Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List of Tables
Table 1. Global Metabotropic Glutamate Receptor 3 Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Metabotropic Glutamate Receptor 3 Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Metabotropic Glutamate Receptor 3 Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Metabotropic Glutamate Receptor 3 Revenue (USD Million) by Region (2016-2021)
Table 5. Global Metabotropic Glutamate Receptor 3 Revenue Market Share by Region (2021-2026)
Table 6. Addex Therapeutics Ltd Corporate Information, Head Office, and Major Competitors
Table 7. Addex Therapeutics Ltd Major Business
Table 8. Addex Therapeutics Ltd Metabotropic Glutamate Receptor 3 Product and Solutions
Table 9. Addex Therapeutics Ltd Metabotropic Glutamate Receptor 3 Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Aevi Genomic Medicine Inc Corporate Information, Head Office, and Major Competitors
Table 11. Aevi Genomic Medicine Inc Major Business
Table 12. Aevi Genomic Medicine Inc Metabotropic Glutamate Receptor 3 Product and Solutions
Table 13. Aevi Genomic Medicine Inc Metabotropic Glutamate Receptor 3 Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Denovo Biopharma LLC Corporate Information, Head Office, and Major Competitors
Table 15. Denovo Biopharma LLC Major Business
Table 16. Denovo Biopharma LLC Metabotropic Glutamate Receptor 3 Product and Solutions
Table 17. Denovo Biopharma LLC Metabotropic Glutamate Receptor 3 Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Domain Therapeutics SA Corporate Information, Head Office, and Major Competitors
Table 19. Domain Therapeutics SA Major Business
Table 20. Domain Therapeutics SA Metabotropic Glutamate Receptor 3 Product and Solutions
Table 21. Domain Therapeutics SA Metabotropic Glutamate Receptor 3 Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Eli Lilly and Company Corporate Information, Head Office, and Major Competitors
Table 23. Eli Lilly and Company Major Business
Table 24. Eli Lilly and Company Metabotropic Glutamate Receptor 3 Product and Solutions
Table 25. Eli Lilly and Company Metabotropic Glutamate Receptor 3 Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Prexton Therapeutics SA Corporate Information, Head Office, and Major Competitors
Table 27. Prexton Therapeutics SA Major Business
Table 28. Prexton Therapeutics SA Metabotropic Glutamate Receptor 3 Product and Solutions
Table 29. Prexton Therapeutics SA Metabotropic Glutamate Receptor 3 Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Global Metabotropic Glutamate Receptor 3 Revenue (USD Million) by Players (2019-2021)
Table 31. Global Metabotropic Glutamate Receptor 3 Revenue Share by Players (2019-2021)
Table 32. Breakdown of Metabotropic Glutamate Receptor 3 by Company Type (Tier 1, Tier 2 and Tier 3)
Table 33. Metabotropic Glutamate Receptor 3 Players Head Office, Products and Services Provided
Table 34. Metabotropic Glutamate Receptor 3 Mergers & Acquisitions in the Past Five Years
Table 35. Metabotropic Glutamate Receptor 3 New Entrants and Expansion Plans
Table 36. Global Metabotropic Glutamate Receptor 3 Revenue (USD Million) by Type (2016-2021)
Table 37. Global Metabotropic Glutamate Receptor 3 Revenue Share by Type (2016-2021)
Table 38. Global Metabotropic Glutamate Receptor 3 Revenue Forecast by Type (2021-2026)
Table 39. Global Metabotropic Glutamate Receptor 3 Revenue by Application (2016-2021)
Table 40. Global Metabotropic Glutamate Receptor 3 Revenue Forecast by Application (2021-2026)
Table 41. North America Metabotropic Glutamate Receptor 3 Revenue by Type (2016-2021) & (USD Million)
Table 42. North America Metabotropic Glutamate Receptor 3 Revenue by Type (2021-2026) & (USD Million)
Table 43. North America Metabotropic Glutamate Receptor 3 Revenue by Application (2016-2021) & (USD Million)
Table 44. North America Metabotropic Glutamate Receptor 3 Revenue by Application (2021-2026) & (USD Million)
Table 45. North America Metabotropic Glutamate Receptor 3 Revenue by Country (2016-2021) & (USD Million)
Table 46. North America Metabotropic Glutamate Receptor 3 Revenue by Country (2021-2026) & (USD Million)
Table 47. Europe Metabotropic Glutamate Receptor 3 Revenue by Type (2016-2021) & (USD Million)
Table 48. Europe Metabotropic Glutamate Receptor 3 Revenue by Type (2021-2026) & (USD Million)
Table 49. Europe Metabotropic Glutamate Receptor 3 Revenue by Application (2016-2021) & (USD Million)
Table 50. Europe Metabotropic Glutamate Receptor 3 Revenue by Application (2021-2026) & (USD Million)
Table 51. Europe Metabotropic Glutamate Receptor 3 Revenue by Country (2016-2021) & (USD Million)
Table 52. Europe Metabotropic Glutamate Receptor 3 Revenue by Country (2021-2026) & (USD Million)
Table 53. Asia-Pacific Metabotropic Glutamate Receptor 3 Revenue by Type (2016-2021) & (USD Million)
Table 54. Asia-Pacific Metabotropic Glutamate Receptor 3 Revenue by Type (2021-2026) & (USD Million)
Table 55. Asia-Pacific Metabotropic Glutamate Receptor 3 Revenue by Application (2016-2021) & (USD Million)
Table 56. Asia-Pacific Metabotropic Glutamate Receptor 3 Revenue by Application (2021-2026) & (USD Million)
Table 57. Asia-Pacific Metabotropic Glutamate Receptor 3 Revenue by Region (2016-2021) & (USD Million)
Table 58. Asia-Pacific Metabotropic Glutamate Receptor 3 Revenue by Region (2021-2026) & (USD Million)
Table 59. South America Metabotropic Glutamate Receptor 3 Revenue by Type (2016-2021) & (USD Million)
Table 60. South America Metabotropic Glutamate Receptor 3 Revenue by Type (2021-2026) & (USD Million)
Table 61. South America Metabotropic Glutamate Receptor 3 Revenue by Application (2016-2021) & (USD Million)
Table 62. South America Metabotropic Glutamate Receptor 3 Revenue by Application (2021-2026) & (USD Million)
Table 63. South America Metabotropic Glutamate Receptor 3 Revenue by Country (2016-2021) & (USD Million)
Table 64. South America Metabotropic Glutamate Receptor 3 Revenue by Country (2021-2026) & (USD Million)
Table 65. Middle East & Africa Metabotropic Glutamate Receptor 3 Revenue by Type (2016-2021) & (USD Million)
Table 66. Middle East & Africa Metabotropic Glutamate Receptor 3 Revenue by Type (2021-2026) & (USD Million)
Table 67. Middle East & Africa Metabotropic Glutamate Receptor 3 Revenue by Application (2016-2021) & (USD Million)
Table 68. Middle East & Africa Metabotropic Glutamate Receptor 3 Revenue by Application (2021-2026) & (USD Million)
Table 69. Middle East & Africa Metabotropic Glutamate Receptor 3 Revenue by Country (2016-2021) & (USD Million)
Table 70. Middle East & Africa Metabotropic Glutamate Receptor 3 Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Metabotropic Glutamate Receptor 3 Picture
Figure 2. Global Metabotropic Glutamate Receptor 3 Revenue Market Share by Type in 2020
Figure 3. LY-3020371
Figure 4. VU-0092273
Figure 5. DT-010991
Figure 6. Others
Figure 7. Metabotropic Glutamate Receptor 3 Revenue Market Share by Application in 2020
Figure 8. Autism Picture
Figure 9. Chronic Pain Picture
Figure 10. Glioma Picture
Figure 11. Others Picture
Figure 12. Global Metabotropic Glutamate Receptor 3 Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 13. Global Metabotropic Glutamate Receptor 3 Revenue and Forecast (2016-2026) & (USD Million)
Figure 14. Global Metabotropic Glutamate Receptor 3 Revenue Market Share by Region (2016-2026)
Figure 15. Global Metabotropic Glutamate Receptor 3 Revenue Market Share by Region in 2020
Figure 16. North America Metabotropic Glutamate Receptor 3 Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Europe Metabotropic Glutamate Receptor 3 Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Asia-Pacific Metabotropic Glutamate Receptor 3 Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. South America Metabotropic Glutamate Receptor 3 Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Middle East and Africa Metabotropic Glutamate Receptor 3 Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. Metabotropic Glutamate Receptor 3 Market Drivers
Figure 22. Metabotropic Glutamate Receptor 3 Market Restraints
Figure 23. Metabotropic Glutamate Receptor 3 Market Trends
Figure 24. Addex Therapeutics Ltd Recent Developments and Future Plans
Figure 25. Aevi Genomic Medicine Inc Recent Developments and Future Plans
Figure 26. Denovo Biopharma LLC Recent Developments and Future Plans
Figure 27. Domain Therapeutics SA Recent Developments and Future Plans
Figure 28. Eli Lilly and Company Recent Developments and Future Plans
Figure 29. Prexton Therapeutics SA Recent Developments and Future Plans
Figure 30. Global Metabotropic Glutamate Receptor 3 Revenue Share by Players in 2020
Figure 31. Metabotropic Glutamate Receptor 3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 32. Global Top 3 Players Metabotropic Glutamate Receptor 3 Revenue Market Share in 2020
Figure 33. Global Top 10 Players Metabotropic Glutamate Receptor 3 Revenue Market Share in 2020
Figure 34. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 35. Global Metabotropic Glutamate Receptor 3 Revenue Share by Type in 2020
Figure 36. Global Metabotropic Glutamate Receptor 3 Market Share Forecast by Type (2021-2026)
Figure 37. Global Metabotropic Glutamate Receptor 3 Revenue Share by Application in 2020
Figure 38. Global Metabotropic Glutamate Receptor 3 Market Share Forecast by Application (2021-2026)
Figure 39. North America Metabotropic Glutamate Receptor 3 Sales Market Share by Type (2016-2026)
Figure 40. North America Metabotropic Glutamate Receptor 3 Sales Market Share by Application (2016-2026)
Figure 41. North America Metabotropic Glutamate Receptor 3 Revenue Market Share by Country (2016-2026)
Figure 42. United States Metabotropic Glutamate Receptor 3 Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 43. Canada Metabotropic Glutamate Receptor 3 Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 44. Mexico Metabotropic Glutamate Receptor 3 Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Europe Metabotropic Glutamate Receptor 3 Sales Market Share by Type (2016-2026)
Figure 46. Europe Metabotropic Glutamate Receptor 3 Sales Market Share by Application (2016-2026)
Figure 47. Europe Metabotropic Glutamate Receptor 3 Revenue Market Share by Country (2016-2026)
Figure 48. Germany Metabotropic Glutamate Receptor 3 Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. France Metabotropic Glutamate Receptor 3 Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. United Kingdom Metabotropic Glutamate Receptor 3 Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. Russia Metabotropic Glutamate Receptor 3 Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Italy Metabotropic Glutamate Receptor 3 Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Asia-Pacific Metabotropic Glutamate Receptor 3 Sales Market Share by Type (2016-2026)
Figure 54. Asia-Pacific Metabotropic Glutamate Receptor 3 Sales Market Share by Application (2016-2026)
Figure 55. Asia-Pacific Metabotropic Glutamate Receptor 3 Revenue Market Share by Region (2016-2026)
Figure 56. China Metabotropic Glutamate Receptor 3 Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Japan Metabotropic Glutamate Receptor 3 Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. South Korea Metabotropic Glutamate Receptor 3 Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. India Metabotropic Glutamate Receptor 3 Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Southeast Asia Metabotropic Glutamate Receptor 3 Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Australia Metabotropic Glutamate Receptor 3 Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. South America Metabotropic Glutamate Receptor 3 Sales Market Share by Type (2016-2026)
Figure 63. South America Metabotropic Glutamate Receptor 3 Sales Market Share by Application (2016-2026)
Figure 64. South America Metabotropic Glutamate Receptor 3 Revenue Market Share by Country (2016-2026)
Figure 65. Brazil Metabotropic Glutamate Receptor 3 Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. Argentina Metabotropic Glutamate Receptor 3 Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Middle East and Africa Metabotropic Glutamate Receptor 3 Sales Market Share by Type (2016-2026)
Figure 68. Middle East and Africa Metabotropic Glutamate Receptor 3 Sales Market Share by Application (2016-2026)
Figure 69. Middle East and Africa Metabotropic Glutamate Receptor 3 Revenue Market Share by Country (2016-2026)
Figure 70. Turkey Metabotropic Glutamate Receptor 3 Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Saudi Arabia Metabotropic Glutamate Receptor 3 Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. UAE Metabotropic Glutamate Receptor 3 Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Methodology
Figure 74. Research Process and Data Source

---